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Abstract
Background: On stopping bisphosphonate treatment, bone 
resorption may increase before evidence of a decrease in bone 
density. Offset of bisphosphonate effect may therefore be 
monitored by measuring C-terminal telopeptide (CTX) following 
long-term bisphosphonate treatment to inform clinical 
decisions on drug holiday.
Methods: Retrospective analysis of 158 patients (83% female, 
mean age 71 years) starting a drug holiday had plasma CTX 
measured at discontinuation (baseline), n=138 and 4 months 
and n=136, and 12 months (n=100). Premenopausal mean CTX 
levels and the least significant change (LSC) detectable were 
used to define target thresholds for bone turnover.
Results: Following long-term bisphosphonate treatment (69% 
alendronic acid, 33% risedronate, mean duration 8 years SD 
2.7), 32% patients had CTX above target (0.19 µg/L). In those 
with baseline CTX below threshold, 28% increased CTX to >0.19 
µg/L and > LSC (0.06 µg/L) by 4 months (mean CTX increase 
0.05 µg/L [95% confidence interval (CI): 0.04–0.06; p<0.0001]) 
and 53% by 12 months (mean CTX increase 0.09 µg/L [95%  
CI: 0.07–0.10; p<0.0001]), whilst 47% had no detectable changes 
in CTX over 12 months.
Conclusion: A third of patients showed inadequate suppression 
of CTX at baseline, despite long-term bisphosphonate 
treatment. Drug holiday may not be appropriate for this group, 
showing a poor therapeutic response or poor adherence. For 
more than a quarter of patients, bisphosphonate effects were 
wearing off at 4 months and around half by 12 months. We 
suggest CTX monitoring could identify those not experiencing 
a sustained bisphosphonate effect, including poorly adherence 
to therapy, and may be used during a drug holiday to prompt 
recommencement of therapy.
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bone remodelling, collagen type 1, risedronic acid, alendronate.
Citation
Statham L, Abdy S, Aspray TJ. Can bone turnover markers help 
to define the suitability and duration of bisphosphonate drug 
holidays? Drugs in Context 2020; 9: 2020-1-3.  
DOI: 10.7573/dic.2020-1-3
Louise Statham MPharm, PGClin Dip, PGCHE, IPresc1,2, Sharon Abdy RN, BSc (Hons)1, 
Terry J Aspray MBBS, MD, FRCP, FRCP(Edinburgh)1,3
1The Bone Clinic, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK; 2Faculty of Health Sciences and Well-being, 
The University of Sunderland, Dale Building, City Campus, Chester Road, Sunderland, SR1 3SD, UK; 3NIHR Biomedical Research Centre, 
Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, NE4 5PL, UK
Can bone turnover markers help to define the suitability and duration of 
bisphosphonate drug holidays?
ACCESS ONLINE
Introduction
Evidence for using 5 years of bisphosphonate (BP) treatment in 
the management of osteoporosis is well established,1,2 though 
the value of continuing treatment beyond this time is less clear. 
The emergence of rare adverse effects with longer-term therapy, 
such as atypical fracture and osteonecrosis of the jaw, has led to 
concerns that bone quality may be not be sustained indefinitely 
with ongoing treatment.3 In addition, several studies have 
demonstrated the continued effect of BPs following treatment 
cessation as a result of their long residency time in the bone.1,2,4 
This has led to the increasing use of so-called drug holidays in 
clinical practice, whereby treatment is interrupted for up to 3 
years to potentially minimise longer-term adverse effects whilst 
remaining at a relatively reduced risk of fracture.5,6 Zoledronic 
acid appears to have the longest duration of action after 
discontinuation, followed by alendronic acid, whilst risedronate 
appears to wear off more quickly, within a year of therapy 
cessation.1,2,4 Whilst these clinical trials have demonstrated 
persistent effects of BPs following treatment cessation, less 
is known about the real-world consequence of stopping BPs. 
Individual effects of BP treatment may vary, as may adherence 
in this setting, so discontinuation of prescription may not be 
associated with persistence of benefit in routine clinical practice. 
It is likely that adherence is higher in randomised controlled trial 
settings, where patients are contacted regularly to encourage 
adherence and are assessed with pill counts and questioning. 
Furthermore, analysis of bone turnover markers in the Fracture 
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Intervention Trial Long-Term Extension (FLEX) trial was based on a 
subgroup of women who had high adherence.1 Application of trial 
findings may not be relevant if adherence has been suboptimal.
Bone turnover markers, including C-terminal crosslinking 
telopeptides of type 1 collagen (CTX), have been used as a 
means of monitoring osteoporosis therapies as a measure 
of metabolic activity of the bone,7,8 with suppression of CTX 
seen on initiation of BP therapy.8,9 Conversely, with treatment 
cessation, CTX levels increase, followed by slower changes 
in bone mineral density (BMD).1 These biomarkers could 
have a role in monitoring patients whilst on a drug holiday 
to ensure persistence of antiresorptive effect. They may also 
aid identification of patients who have poor adherence at 
baseline and would therefore not benefit from a drug holiday. 
We recognise that there are some circumstances in which 
this would be less appropriate, such as in poor renal function 
(CTX is renally cleared) or where a recent fracture has occurred 
(increased bone remodelling).
Our aim was to analyse changes in CTX on stopping 
long-term BPs in a real-world population to see whether 
persistence of BP effect was maintained. Key objectives 
were to assess whether long-term use of BPs results in an 
appropriate CTX level below the premenopausal mean 
target; to identify whether CTX increases are evident at 4 
and 12 months to indicate return to normal bone turnover; 
and to identify any variance in persistence of effect between 
different BPs.
Methods
Patients attending an outpatient specialist bone clinic, who 
had been prescribed BP therapy for at least 5 years, from June 
2012 until October 2014, were identified from monitoring 
records (n=158). This coincided with a change in routine clinical 
practice, as patients were offered a supervised drug holiday 
from therapy. This comprised a baseline measurement of 
serum CTX with subsequent reassessment at 4 and 12 months. 
Retrospective data were collected on age, gender, drug, 
duration of BP therapy and serum CTX level on initiation of 
drug holiday (‘baseline’ n=138) and at 4 months (n=136) and 12 
months (n=100) following treatment cessation.
Least significant change (LSC) from baseline values were 
calculated for CTX at 4 and 12 months, using a one-sided 
probability of 0.05 applied to the formula √2 × 1.65 × CV, where 
CV is the combined coefficient of variation (√[CVanalytic2 + 
CVintra-individual2]).8 Analytic coefficient of variation was 
calculated from local laboratory data (5.8%, Roche immunoassay; 
intra-individual coefficient of variation was identified from the 
literature [13.4%]).10 The LSC was 33%; absolute LSC based on the 
premenopausal mean value from earlier studies (0.19 µg/L) was 
0.06 µg/L.8,11,12
Comparisons of change in CTX at baseline, 4 and 12 months 
were made using t-tests, and 95% confidence intervals were 
constructed from these data (all STATA 15.0, Texas). CTX levels 
were compared to a target healthy premenopausal mean level 
(0.19 µg/L) at baseline, 4 and 12 months; normal bone turnover 
was said to have resumed if CTX was above target (0.19 µg/L) 
and above absolute LSC (0.06 µg/L). This was incorporated into 
a clinical algorithm for considering drug holidays.13
This paper presents an analysis of routine patient care, which was 
evaluated as a clinical service development. Data were collected 
in accordance with the Caldicott principles, which govern the 
handling of patient information in the United Kingdom, and the 
results have been used to inform clinical practice locally and 
service development (Caldicott approval 3082, Newcastle upon 
Tyne Hospitals NHS Foundation Trust, date 12 March 2014).
Results
Data were available for 131 women and 27 men, with a mean 
age of 71 years who had received BP therapy for a mean 
duration of 8 years (SD 2.74, range 3–15 years). The majority 
of participants had been taking alendronic acid (59%, n=93) 
or risedronate (33%, n=52) with other BPs accounting for a 
small number of cases (ibandronic acid 6%, n=9; zoledronic 
acid 2%, n=3; cyclical etidronate 1%, n=1). There were two 
patients with a CTX level ≥ 0.51 µg/L who were excluded from 
further analysis.11 CTX levels were available at both baseline 
and 4 months for 117 patients, at both 4 and 12 months for 89 
patients and at all three time points for 83 patients.
At baseline, 68% of patients had a CTX level below the 
premenopausal mean target. In this subset of patients, there 
was a mean increase in CTX by 0.05 µg/L (95% confidence 
interval [CI]: 0.04–0.06; p<0.0001) at 4 months and an increase 
by 0.09 µg/L (95% CI: 0.07–0.10; p<0.0001) at 12 months. This 
represented an increase in CTX by the LSC that was also above 
the premenopausal mean in 28% patients at 4 months and 53% 
patients at 12 months. In contrast, for those who had a baseline 
CTX above the premenopausal mean, there was no significant 
difference in CTX at 4 months (+0.01 µg/L; 95% CI: 0.01–0.04; 
p=0.31), though a significant increase was seen by 12 months 
(+0.05 µg/L; 95% CI: 0.01–0.09; p=0.01) (see Figure 1).
Overall, following BP cessation, at 4 months, mean (median, 
interquartile range [IQR], %) serum CTX levels increased by 0.04 
µg/L (0.04, 0.01–0.08, 42%) with a rise by at least the LSC (of 
33%) in 47% patients. At 12 months, there was a rise by 0.08 µg/L 
(0.09, 0.04–0.12, 59%) with an increase by at least the LSC in 69%.
There was a greater increase in CTX on stopping risedronate 
at 4 months (+0.05 µg/L [0.06, 0.03–0.07]) and 12 months (0.09 
µg/L [0.06, 0.07–0.12]) than alendronic acid (+0.04 µg/L [0.06, 
0.02–0.05]) at 4 months and (0.07 µg/L [0.07, 0.05–0.09]) at 12 
months, although this difference was not statistically significant 
(p=0.31 and p=0.12, respectively).
Discussion
We found that the majority of patients (68%) taking long-term 
BPs did appear to have an appropriate level of CTX suppression 
Statham L, Abdy S, Aspray TJ. Drugs in Context 2020; 9: 2020-1-3. DOI: 10.7573/dic.2020-1-3 3 of 5
ISSN: 1740-4398
ORIGINAL RESEARCH – Bone turnover markers: monitoring in bisphosphonate drug holidays drugsincontext.com
at the time of treatment cessation, meeting the target CTX 
threshold at or below the target premenopausal mean 
level (0.19 µg/L). These patients, who had appropriate CTX 
suppression at baseline, saw increases in CTX by the LSC and to 
above the premenopausal mean at 4 and 12 months in 28% and 
53% of patients, respectively, demonstrating potential return to 
normal bone turnover within these timeframes. The remaining 
32% of patients who did not meet the premenopausal target 
mean at baseline, despite taking long-term BP treatment, saw 
a significant rise in CTX by 12 months, but not as soon as 4 
months.
We used the definition of an appropriate level of CTX 
suppression as being at or below a healthy premenopausal 
mean, as the lower half of the premenopausal reference 
intervals have been used as a target for those on BP 
treatment and gives an indication of appropriate 
suppression of bone turnover by BP.11 This revealed a 
significant number of patients who did not demonstrate 
biochemical evidence of suppression of bone resorption 
despite being on BP treatment. There are several possible 
explanations for this, including lack of response to 
treatment as a result of poor adherence, malabsorption, 
drug interactions, improper administration, limitations 
in interpreting CTX levels or for unknown reasons. Some 
patients may have had a partial response to treatment with 
suppression of CTX to a level above the premenopausal 
mean. One of the most likely explanations for this finding 
is the impact of adherence, as previous studies have found 
adherence to be poor in patients on oral BPs14 and bone 
turnover markers have been used to identify patients who 
are not adherent to BP therapy.12 This is supported by the 
lack of significant change in CTX at 4 months in those who 
did not reach the CTX target at baseline; consequently, no 
real change was seen on ‘cessation’ of treatment. Whilst a 
significant difference was noted in this group at 12 months, 
the confidence interval was undoubtedly wider and 
therefore less reliable [Figure 1]. The proportion of patients 
who did not appear to reach the target CTX response despite 
being on long-term treatment is concerning. The level 
of adherence should always be fully considered prior to 
initiation of a drug holiday and, as patients may not always 
admit to or realise the extent of their own level of adherence, 
estimation of bone turnover markers may add confidence 
and support the decision-making process from this point 
of view.
The rise in CTX following BP treatment is in line with 
published literature,1,2,4 with some patients experiencing 
a sustained response to BPs for up to 12 months post 
treatment cessation. The early increases in CTX at 4 months 
were not explained by the use of different BPs in our study, 
as although we saw increased percentage change in CTX 
in risedronate compared to alendronic acid, this was not 
statistically significant. It is possible that this may have 
become significant with an increased sample size as the 
number of patients taking risedronate was comparatively 
smaller.
We considered that the two-thirds of patients who were 
established on BP and maintained a target CTX after at 
least 5 years of treatment could be deemed suitable for a 
drug holiday to reduce the risk of rare longer-term adverse 
effects such as atypical fracture. By 12 months, over half 
of patients had a significant rise in CTX, which was also 
above the premenopausal mean, and we concluded that 
recommencement of treatment may be appropriate. It is 
clear that in a real-world clinical setting, longer-term BP 
persistence is not sustained for all patients, and therefore 
it is important that treatment is reviewed. Those who 
have elevated CTX levels are likely to be at higher risk of 
osteoporosis rather than atypical fracture and therefore may 
be less suitable for drug holiday. These findings have been 
used to guide our clinical practice in the management of 
long-term BP treatment.13
Assessment of BMD plays a particularly important role in 
assessing fracture risk at the time of deliberating a drug 
holiday, contributing to estimated 10-year fracture risk 
(FRAX/NOGG). We believe that bone turnover markers, 
which change much more rapidly than changes in 
bone density, could help to support early decisions on 
drug holiday monitoring to ensure that non-persistent 
responders who are likely to be at higher risk of low 
trauma fracture and may be less suitable for a drug holiday 
are identified. The markers could also potentially help 
to determine timing of recommencement of therapy. 
Current guidance,15 which was not available at the time 
of conducting this study, recommends that where a drug 
holiday is initiated, patients should be reviewed after  
Figure 1. CTX at 0, 4 and 12 months for patients 
below or above premenopausal mean 
CTX level at baseline.
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18 months to 3 years, or sooner if a fracture occurs. An 
increase in bone turnover could occur in a significant number 
of patients before changes in BMD can be seen and could 
potentially help to support decisions at an earlier stage. It 
would therefore be useful to apply NOGG thresholds to our 
CTX/LSC data with fracture, BMD and steroid history in order 
to assess application of these parameters to a clinical practice 
setting.
We recognise that whilst this analysis of our clinical data gives 
insight into the continued impact of BPs on bone resorption 
following cessation, the size of the study group means 
that impact on risk of fracture is not available. We did not 
perform a sample size calculation, as we studied all patients 
who had been initiated on a drug holiday in our clinic at the 
point of data collection. Serum CTX levels were assessed as 
per clinical practice; therefore, samples were always taken 
in the morning, though fasting states were not guaranteed; 
the healthy premenopausal reference intervals used also 
represented non-fasting levels. Other factors that may affect 
the interpretation of CTX reading, such as impaired renal 
function, liver function or recent fracture, were not separately 
analysed, though they should also be properly considered 
when making clinical decisions regarding drug holidays. We 
also note that the change in bone turnover markers after 
discontinuing therapy varies between antiresorptive agents 
and, particularly for denosumab, persistence of effect is 
much shorter.16,17 We would therefore not recommend this 
approach to monitoring off-set of therapy for denosumab, 
although we have adopted this practice for oral BPs in our 
clinic.
It was beyond the scope of this study to consider other 
turnover markers, as CTX is currently the only marker that 
we have available in our clinical setting. It is possible that 
markers of bone formation such as procollagen type 1 N 
propeptide (P1NP) could be used to assess bone turnover 
following BP cessation to indirectly measure BP effect, 
though changes in levels would not be as rapid. P1NP does 
have other advantages in terms of having less variability with 
respect to circadian rhythm and being less affected by food 
intake.
In summary, this paper demonstrates that in a real-world 
setting, persistent BP effect may not be evident in some 
patients, despite at least 5 years of BP treatment. Significant 
increases in the bone turnover marker CTX were seen as soon 
at 4 months following treatment cessation in some patients. 
The use of bone turnover markers may potentially aid clinical 
decision-making to highlight patients who may be less 
suitable for a drug holiday due to perceived lack of response 
despite long-term treatment or who should potentially restart 
treatment sooner. We suggest a practical threshold/LSC 
approach for aiding decisions related to drug holidays in a 
clinical practice setting.
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